Intentional upregulation of ICAM-1 with the therapeutic goal of enhancing recognition and killing by CAR T cells, while possibly favorable in terms of cytolytic targeting of tumor cells, must be thoroughly examined in each case given the capacity of ICAM-1 to promote pro-tumorigenic signaling and metastasis. The gene discussed is ICAM1; the disease is neoplasm.